Path ID: DB05679_MESH_D011565_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000069549 | ustekinumab | Drug |
| UniProt:P29460 | Interleukin-12 subunit beta | Protein |
| GO:0035722 | interleukin-12-mediated signaling pathway | BiologicalProcess |
| GO:0038155 | interleukin-23-mediated signaling pathway | BiologicalProcess |
| GO:0006954 | inflammatory response | BiologicalProcess |
| MESH:D011565 | Psoriasis | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Ustekinumab | DECREASES ACTIVITY OF | Interleukin-12 Subunit Beta |
| Interleukin-12 Subunit Beta | POSITIVELY REGULATES | Interleukin-12-Mediated Signaling Pathway |
| Interleukin-12 Subunit Beta | POSITIVELY REGULATES | Interleukin-23-Mediated Signaling Pathway |
| Interleukin-12-Mediated Signaling Pathway | POSITIVELY REGULATES | Inflammatory Response |
| Interleukin-23-Mediated Signaling Pathway | POSITIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Psoriasis |
Comment: This drug binds to the p-40 subunit (UniProt:P29460) of both IL-12 (UniProt:P29459) and IL-23 (UniProt:Q9NPF7) so that they subsequently cannot bind to their receptors (https://en.wikipedia.org/wiki/Ustekinumab#Mechanism_of_action).
Reference: